Trials / Recruiting
RecruitingNCT06365840
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- ImmuneOncia Therapeutics Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMC-001 | All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes. |
Timeline
- Start date
- 2025-01-13
- Primary completion
- 2027-06-30
- Completion
- 2029-08-01
- First posted
- 2024-04-15
- Last updated
- 2026-04-17
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06365840. Inclusion in this directory is not an endorsement.